This is a medicine used to treat HIV. It contains three different drugs working together to fight the virus. It's often taken as a pill, usually once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Complera (Emtricitabine/Rilpivirine/Tenofovir) for HIV Infection?
Complera is a prescription HIV medicine that combines three antiviral drugs in one daily tablet: emtricitabine, rilpivirine and tenofovir disoproxil fumarate. Because the three drugs together make a full treatment regimen, it is taken on its own rather than added to other HIV medicines. It is approved for adults and for children who weigh at least 35 kg (about 77 pounds). It is used in two situations. For someone starting HIV treatment for the first time, it is an option only when the viral load (the amount of HIV in the blood) is 100,000 copies per milliliter or lower, because rilpivirine-based treatment fails more often when the starting viral load is higher. It can also replace another regimen for someone whose HIV has been controlled, with a viral load below 50 copies per milliliter, for at least six months, as long as treatment has not failed before and the virus is not known to be resistant to any of its ingredients. Odefsey is a closely related tablet that contains emtricitabine and rilpivirine with tenofovir alafenamide, a newer form of tenofovir, in place of tenofovir disoproxil fumarate. It is approved from 25 kg and has different kidney limits. The two are not interchangeable without the prescriber's guidance.
HIV copies itself by turning its genetic material into DNA that it can insert into a person's immune cells. It needs an enzyme called reverse transcriptase to do this. All three ingredients in Complera block that enzyme, but in two different ways. Emtricitabine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs). They resemble the building blocks of DNA, so the virus picks them up by mistake, and the DNA chain it is building stops short. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It attaches directly to the enzyme and stops it working. HIV treatment always combines several drugs like this, because a single drug on its own lets resistant virus emerge quickly. With fewer new copies of HIV being made, the viral load falls and the immune system has a chance to recover. The medicine does not cure HIV. The virus remains in the body and becomes active again if treatment stops.
Complera is one tablet taken by mouth once a day with food. The label specifies food because rilpivirine levels depend on it, and a protein drink does not count as a meal. Taking it at about the same time each day and not missing doses keeps drug levels steady; repeated gaps can let the virus become resistant to these medicines. Some stomach remedies lower rilpivirine levels and need careful timing. Antacids (such as calcium carbonate or magnesium and aluminum products) should be taken at least 2 hours before or at least 4 hours after Complera. Acid reducers in the H2 blocker group, such as famotidine, should be taken at least 12 hours before or at least 4 hours after it. Stronger acid blockers called proton pump inhibitors cannot be used with it at all (see Interactions & Warnings). Before starting, the care team tests for hepatitis B and checks kidney function. Complera is not recommended when kidney function is moderately or severely reduced (an estimated creatinine clearance, a blood-test measure of how well the kidneys filter, below 50 mL per minute), because its doses cannot be adjusted within a fixed tablet. People who need the tuberculosis medicine rifabutin take an extra rilpivirine tablet (Edurant) each day for as long as they are on rifabutin.
Many people take Complera with few problems. In studies, the most common effects of its ingredients included nausea, diarrhea, headache, tiredness, dizziness, trouble sleeping, unusual dreams and rash. A mild to moderate rash is most likely in the first four to six weeks and should still be reported to the care team. A rash that comes with fever, blisters, sores in the mouth, red or inflamed eyes, swelling of the face, lips, tongue or throat, or signs of liver trouble can be a serious allergic reaction. Stop taking Complera and get medical help right away if this happens. Rilpivirine has been linked to low mood, depression and, rarely, suicidal thoughts. Severe depressive symptoms or thoughts of self-harm call for immediate medical evaluation, so the team can judge whether the medicine is contributing. Other possible problems are monitored with blood and urine tests rather than felt early. Liver inflammation is more likely in people who already have hepatitis B or C. Tenofovir disoproxil fumarate can harm the kidneys, occasionally severely, and can slightly lower bone density; persistent bone pain or muscle weakness is worth reporting because it can be a sign of kidney-related bone thinning.
People who also have hepatitis B need particular care. Emtricitabine and tenofovir both suppress hepatitis B, and stopping Complera can let the hepatitis B flare severely, occasionally to the point of liver failure. This is why everyone is tested for hepatitis B before starting, and why no one should stop Complera without talking to the prescriber first. Someone with both infections who does stop it needs close liver monitoring for several months. Several medicines can lower rilpivirine levels enough to make treatment fail and allow resistance. These must not be combined with Complera: proton pump inhibitors for heartburn and ulcers (such as omeprazole, esomeprazole or pantoprazole); the seizure medicines carbamazepine, oxcarbazepine, phenobarbital and phenytoin; the tuberculosis antibiotics rifampin and rifapentine; more than a single dose of the steroid dexamethasone; and the herbal supplement St. John's wort. Other combinations need a plan rather than a ban. High-dose or repeated use of nonsteroidal anti-inflammatory (NSAID) pain relievers such as ibuprofen can strain the kidneys alongside tenofovir. Some antibiotics (clarithromycin, erythromycin) and antifungals raise rilpivirine levels, and medicines known to disturb the heart's rhythm may call for an alternative regimen. Methadone doses sometimes need adjusting. Complera should not be taken with other HIV medicines, since it is already a complete regimen. Pharmacists and every prescriber should know about all prescriptions, over-the-counter medicines and supplements. People who become pregnant while their HIV is well controlled on Complera can usually continue it, with closer viral load checks because rilpivirine levels fall during pregnancy. Registry data have not shown an increase in major birth defects with its ingredients. The label advises people with HIV not to breastfeed because HIV can pass to a baby in breast milk, so feeding plans are worth discussing with the care team.
The goal of treatment is to bring the viral load down and keep it low. Regular blood tests track the viral load and CD4 count (a measure of immune strength), especially in the first months and after any switch. Kidney function, urine tests and, where relevant, liver tests are checked on a schedule too. HIV treatment is lifelong. Keeping the viral load suppressed lets the immune system recover, helps people live longer, healthier lives and reduces the chance of passing HIV to others. Steady daily dosing with food is the main thing a person controls, since missed doses can let the virus become resistant. If side effects, kidney changes, a new medicine that cannot be combined with it, or a rising viral load become a problem, the care team can switch to another regimen. Any change should be planned with them, particularly for people with hepatitis B.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Complera (Emtricitabine/Rilpivirine/Tenofovir), what you've noticed, or ask the community a question.